Literature DB >> 19860002

Hepatitis C virus genotype 3a infection and hepatocellular carcinoma: Pakistan experience.

Muhammad Idrees1, Shazia Rafique, Irshadur Rehman, Haji Akbar, Muhammad-Zubair Yousaf, Sadia Butt, Zunaira Awan, Sobia Manzoor, Madiha Akram, Mahwish Aftab, Bushra Khubaib, Sheikh Riazuddin.   

Abstract

AIM: To assess the association between chronic hepatitis C virus (HCV) infection and hepatocellular carcinoma (HCC) in Pakistan, and the genotype distribution among these HCC patients.
METHODS: One hundred and sixty-one subjects with HCC were included in this study. Liver biopsy was performed on 145 of the patients; sixteen were excluded because they failed to fulfill the inclusion criteria. Qualitative polymerase chain reaction (PCR) was performed for hepatitis B virus and HCV. Samples positive for HCV RNA were genotyped using genotype-specific PCR and confirmed by HCV 5' noncoding region sequencing analysis.
RESULTS: Chronic HCV infection was identified a major risk factor (63.44% of tested HCC patients) for the development of HCC. The time from HCV infection to appearance of cancer was 10-50 years. In the HCC patient population, broader distributions of genotypes were present with genotype 3a as the predominant genotype. Using the type-specific genotyping method, we found HCV genotype 3a in 40.96%, 3b in 15.66%, 1a in 9.63%, and 1b in 2.40% of HCC tissue samples. About 28% of cases were found with mixed genotypes. Two cases were unable to be genotyped because of low viral load. Sixty-six percent of treated patients with cirrhosis had an end of treatment response, but unfortunately they relapsed quickly when the treatment was discontinued, and HCC developed during a median 3.8 years.
CONCLUSION: There was a strong association between chronic HCV infection and HCC in Pakistan, and between HCV genotype 3a and HCC.

Entities:  

Mesh:

Year:  2009        PMID: 19860002      PMCID: PMC2768888          DOI: 10.3748/wjg.15.5080

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  43 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

2.  Estimating future hepatitis C morbidity, mortality, and costs in the United States.

Authors:  J B Wong; G M McQuillan; J G McHutchison; T Poynard
Journal:  Am J Public Health       Date:  2000-10       Impact factor: 9.308

3.  International trends and patterns of primary liver cancer.

Authors:  K A McGlynn; L Tsao; A W Hsing; S S Devesa; J F Fraumeni
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

4.  Hepatitis B epidemiology in Asia, the Middle East and Africa.

Authors:  F André
Journal:  Vaccine       Date:  2000-02-18       Impact factor: 3.641

Review 5.  Hepatocellular carcinoma in the developing world.

Authors:  J O Ogunbiyi
Journal:  Semin Oncol       Date:  2001-04       Impact factor: 4.929

6.  Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group.

Authors:  M H Chang; C J Chen; M S Lai; H M Hsu; T C Wu; M S Kong; D C Liang; W Y Shau; D S Chen
Journal:  N Engl J Med       Date:  1997-06-26       Impact factor: 91.245

7.  Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.

Authors:  T Poynard; J McHutchison; G L Davis; R Esteban-Mur; Z Goodman; P Bedossa; J Albrecht
Journal:  Hepatology       Date:  2000-11       Impact factor: 17.425

Review 8.  Natural history of HCV infection.

Authors:  T Poynard; V Ratziu; Y Benhamou; P Opolon; P Cacoub; P Bedossa
Journal:  Baillieres Best Pract Res Clin Gastroenterol       Date:  2000-04

9.  Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience.

Authors:  D S Chen; G C Kuo; J L Sung; M Y Lai; J C Sheu; P J Chen; P M Yang; H M Hsu; M H Chang; C J Chen
Journal:  J Infect Dis       Date:  1990-10       Impact factor: 5.226

10.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

View more
  32 in total

1.  Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease.

Authors:  Jinhong Ren; Isabel Ojeda; Maulik Patel; Michael E Johnson; Hyun Lee
Journal:  Bioorg Med Chem Lett       Date:  2019-06-08       Impact factor: 2.823

Review 2.  Hepatitis C virus infection: Are there still specific problems with genotype 3?

Authors:  Claire Gondeau; Georges Philippe Pageaux; Dominique Larrey
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

3.  Inhibition of core gene of HCV 3a genotype using synthetic and vector derived siRNAs.

Authors:  Saba Khaliq; Shah Jahan; Bushra Ijaz; Waqar Ahmad; Sultan Asad; Asim Pervaiz; Baila Samreen; Mahwish Khan; Sajida Hassan
Journal:  Virol J       Date:  2010-11-13       Impact factor: 4.099

4.  Epidemiological manifestations of hepatitis C virus genotypes and its association with potential risk factors among Libyan patients.

Authors:  Hana A Elasifer; Yossif M Agnnyia; Basher A Al-Alagi; Mohamed A Daw
Journal:  Virol J       Date:  2010-11-13       Impact factor: 4.099

5.  Hepatitis C genotype influences post-liver transplant outcomes.

Authors:  Isabel Campos-Varela; Jennifer C Lai; Elizabeth C Verna; Jacqueline G O'Leary; R Todd Stravitz; Lisa M Forman; James F Trotter; Robert S Brown; Norah A Terrault
Journal:  Transplantation       Date:  2015-04       Impact factor: 4.939

Review 6.  Hepatitis C virus prevalence and genotype distribution in Pakistan: Comprehensive review of recent data.

Authors:  Muhammad Umer; Mazhar Iqbal
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

7.  Hepatocellular carcinoma in pakistan: where do we stand?

Authors:  Amna Subhan Butt; Zaigham Abbas; Wasim Jafri
Journal:  Hepat Mon       Date:  2012-10-10       Impact factor: 0.660

8.  Changing pattern of clinical epidemiology on hepatitis C virus infection in southwest china.

Authors:  Zehui Yan; Ke Fan; Yuming Wang; Yi Fan; Zhaoxia Tan; Guohong Deng
Journal:  Hepat Mon       Date:  2012-03-28       Impact factor: 0.660

9.  A comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI).

Authors:  Waqar Ahmad; Bushra Ijaz; Fouzia T Javed; Sana Gull; Humaira Kausar; Muhammad T Sarwar; Sultan Asad; Imran Shahid; Aleena Sumrin; Saba Khaliq; Shah Jahan; Asim Pervaiz; Sajida Hassan
Journal:  BMC Gastroenterol       Date:  2011-04-21       Impact factor: 3.067

10.  Role of HCV Core gene of genotype 1a and 3a and host gene Cox-2 in HCV-induced pathogenesis.

Authors:  Shah Jahan; Saba Khaliq; Bushra Ijaz; Waqar Ahmad; Sajida Hassan
Journal:  Virol J       Date:  2011-04-01       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.